Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Tumor necrosis factor: pleiotropic cytokine].

S Chouaib1, E Robinet, A Zyad

  • 1Laboratoire d'immunologie URA-1156 CNRS, Institut Gustave-Roussy, Villejuif, France.

Bulletin Du Cancer
|January 1, 1992
PubMed
Summary

Tumor Necrosis Factor-alpha (TNF-alpha) shows anti-cancer potential but faces limitations. Understanding TNF-alpha

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor microenvironment-induced tumor cell plasticity: relationship with hypoxic stress and impact on tumor resistance.

Frontiers in oncology·2023
Same author

Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.

Oncogene·2016
Same author

The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development.

Oncogene·2016
Same author

The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development.

Oncogene·2015
Same author

Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept.

Gene therapy·2014

Area of Science:

  • Biochemistry
  • Immunology
  • Oncology

Context:

  • Tumor Necrosis Factor-alpha (TNF-alpha) is a key mediator in cellular immunity, inflammation, and pathogenesis of various diseases, including cancer.
  • While TNF-alpha exhibits cytotoxic effects on tumor cells in vitro and has been explored as an anticancer agent, its precise biochemical mechanisms remain largely unknown.
  • Clinical trials with recombinant TNF-alpha have shown limited therapeutic effects due to TNF-alpha resistance and systemic toxicity.

Purpose:

  • To elucidate the biochemical basis of TNF-alpha's cytotoxic action against tumor cells.
  • To clarify the molecular mechanisms underlying TNF-alpha susceptibility and resistance.
  • To explore innovative therapeutic strategies, such as gene therapy, for enhancing TNF-alpha's efficacy in antitumor therapy.

Summary:

  • TNF-alpha, initially noted for inducing tumor necrosis, possesses cytotoxic properties against cancer cells.
  • Despite its immunomodulatory roles, the exact biochemical pathways of TNF-alpha's cell-killing ability and the reasons for tumor resistance are not fully understood.
  • Clinical applications of TNF-alpha as an anticancer agent are hindered by resistance and toxicity, necessitating further research into lysis processes and resistance modulation.

Impact:

  • Elucidating TNF-alpha's cytotoxic mechanisms and resistance factors is crucial for developing effective antitumor therapies.
  • Understanding TNF-alpha's role in immunity and inflammation can inform strategies for treating autoimmune, infectious, and cancerous diseases.
  • Advancements in TNF-alpha research, including gene therapy, hold promise for overcoming current limitations and improving cancer treatment outcomes.

Related Experiment Videos